Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April

Windtree Therapeutics Inc WINT has completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

  • The study enrolled 60 patients with severe heart failure and systolic blood pressure (SBP) between 75 and 90 mmHg. 
  • The study drug was administered over 24 hours. The primary endpoint is the SBP profile over the first 6 hours after initiating the infusion. 
  • Secondary endpoints will include various assessments of blood pressure changes over 24 hours and measures associated with safety and tolerability. 
  • All patients will complete a 30-day follow-up before database lock and generation of topline data.
  • Topline data is expected in April.
  • Cardiogenic shock is a condition that occurs when the heart is failing significantly and cannot pump enough blood and oxygen to the brain, kidneys, and other vital organs. 
  • Istaroxime is a first-in-class, dual mechanism therapy designed to improve systolic and diastolic cardiac function.
  • Price Action: WINT shares are up 1.02% at $0.95 during the market session on the last check Tuesday.
Loading...
Loading...
WINT Logo
WINTWindtree Therapeutics Inc
$0.9000-11.8%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
0.29
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...